

John Petrie

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4738945/publications.pdf](https://exaly.com/author-pdf/4738945/publications.pdf)

Version: 2024-02-01

108
papers

7,403
citations

64264

40
h-index

50275

82
g-index

113
all docs

113
docs citations

113
times ranked

10701
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Canadian Journal of Cardiology, 2018, 34, 575-584.	1.7	1,060
2	Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. JAMA - Journal of the American Medical Association, 2015, 313, 37.	7.1	472
3	Direct Activation of AMP-activated Protein Kinase Stimulates Nitric-oxide Synthesis in Human Aortic Endothelial Cells. Journal of Biological Chemistry, 2003, 278, 31629-31639.	3.5	316
4	Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study. PLoS Medicine, 2012, 9, e1001321.	8.5	278
5	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation, 2021, 143, 516-525.	5.0	276
6	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology, the, 2021, 9, 82-93.	11.0	262
7	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 597-609.	11.0	260
8	Endothelial Nitric Oxide Production and Insulin Sensitivity. Circulation, 1996, 93, 1331-1333.	5.0	256
9	Detailed Physiologic Characterization Reveals Diverse Mechanisms for Novel Genetic Loci Regulating Glucose and Insulin Metabolism in Humans. Diabetes, 2010, 59, 1266-1275.	0.9	239
10	Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clinical Science, 2000, 98, 531-535.	4.4	198
11	Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care, 2020, 43, 250-260.	9.3	195
12	The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia, 2010, 53, 809-820.	6.6	182
13	Insulin resistance in type 1 diabetes: what is "double diabetes"™ and what are the risks?. Diabetologia, 2013, 56, 1462-1470.	6.6	179
14	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology, the, 2020, 8, 301-312.	11.0	177
15	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation, 2018, 138, 2774-2786.	5.0	148
16	Effects of Metformin on Microvascular Function and Exercise Tolerance in Women With Angina and Normal Coronary Arteries. Journal of the American College of Cardiology, 2006, 48, 956-963.	5.6	132
17	Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations. Diabetes Care, 2017, 40, 1614-1621.	9.3	119
18	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes and Endocrinology, the, 2021, 9, 46-52.	11.0	110

#	ARTICLE	IF	CITATIONS
19	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.8	106
20	Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs. <i>Diabetes Care</i> , 2015, 38, 716-722.	9.3	100
21	INSULIN AS A VASCULAR HORMONE: IMPLICATIONS FOR THE PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASE. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1998, 25, 175-184.	2.0	88
22	N-Glycan Profile and Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 79-87.	9.3	81
23	One-Hour Plasma Glucose Identifies Insulin Resistance and β -Cell Dysfunction in Individuals With Normal Glucose Tolerance. <i>Diabetes Care</i> , 2010, 33, 2090-2097.	9.3	78
24	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. <i>Diabetologia</i> , 2016, 59, 2106-2113.	6.6	72
25	Improving the clinical value and utility of CGM systems: issues and recommendations. <i>Diabetologia</i> , 2017, 60, 2319-2328.	6.6	70
26	Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. <i>BMC Nephrology</i> , 2017, 18, 163.	1.9	69
27	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. <i>Diabetes Care</i> , 2021, 44, 390-398.	9.3	69
28	Effect of Socioeconomic Status on Mortality Among People With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1127-1132.	9.3	66
29	Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. <i>Diabetologia</i> , 2015, 58, 862-870.	6.6	64
30	Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. <i>Diabetologia</i> , 2020, 63, 229-241.	6.6	62
31	Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. <i>Journal of Hypertension</i> , 2017, 35, 493-500.	0.5	59
32	A new perspective on metformin therapy in type 1 diabetes. <i>Diabetologia</i> , 2017, 60, 1594-1600.	6.6	59
33	Dietary Sodium Restriction Impairs Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1552-1557.	3.7	58
34	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. <i>Diabetes Care</i> , 2018, 41, 2010-2018.	9.3	50
35	Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology. <i>Biochemical Pharmacology</i> , 2011, 81, 471-477.	4.6	49
36	Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review. <i>Clinical Science</i> , 2018, 132, 1699-1709.	4.4	49

#	ARTICLE	IF	CITATIONS
37	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. <i>BMC Medicine</i> , 2019, 17, 165.	5.7	49
38	Glycaemic control trends in people with type 1 diabetes in Scotland 2004–2016. <i>Diabetologia</i> , 2019, 62, 1375-1384.	6.6	48
39	Identification of novel biomarkers to monitor β -cell function and enable early detection of type 2 diabetes risk. <i>PLoS ONE</i> , 2017, 12, e0182932.	2.4	47
40	Metformin, lipids and atherosclerosis prevention. <i>Current Opinion in Lipidology</i> , 2018, 29, 346-353.	2.8	46
41	Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012–2014): a population-based observational study. <i>Diabetologia</i> , 2018, 61, 108-116.	6.6	44
42	Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes: A National Population-Based Retrospective Cohort Study. <i>Diabetes Care</i> , 2022, 45, 83-91.	9.3	41
43	Metformin and cardiorenal outcomes in diabetes: A reappraisal. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 904-915.	4.6	40
44	THE EUGLYCAEMIC HYPERINSULINAEMIC CLAMP: AN EVALUATION OF CURRENT METHODOLOGY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1997, 24, 513-518.	2.0	39
45	Plasma HDL-cholesterol and triglycerides, but not LDL-cholesterol, are associated with insulin secretion in non-diabetic subjects. <i>Metabolism: Clinical and Experimental</i> , 2017, 69, 33-42.	3.7	38
46	The cardiovascular safety of incretin-based therapies: a review of the evidence. <i>Cardiovascular Diabetology</i> , 2013, 12, 130.	7.1	37
47	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. <i>Diabetologia</i> , 2019, 62, 621-632.	6.6	35
48	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. <i>Diabetologia</i> , 2020, 63, 788-798.	6.6	35
49	Metformin in adults with type 1 diabetes: Design and methods of REDucing Metformin Vascular Adverse Lesions (REMOVAL): an international multicentre trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 509-516.	4.6	34
50	Excess Cardiovascular Risk in Type 1 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 744-747.	5.0	32
51	Ethnic Differences in Glycaemic Control in People with Type 2 Diabetes Mellitus Living in Scotland. <i>PLoS ONE</i> , 2013, 8, e83292.	2.4	31
52	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-64.	3.0	31
53	Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. <i>Diabetologia</i> , 2023, 66, 3-22.	6.6	31
54	Metabolic characteristics of prehypertension: role of classification criteria and gender. <i>Journal of Hypertension</i> , 2009, 27, 2394-2402.	0.5	27

#	ARTICLE	IF	CITATIONS
55	Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. <i>Diabetes Care</i> , 2022, 45, 3058-3074.	9.3	27
56	Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetologia</i> , 2011, 54, 2000-2008.	6.6	26
57	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. <i>Diabetologia</i> , 2020, 63, 636-647.	6.6	25
58	Genetic Landscape of the ACE2 Coronavirus Receptor. <i>Circulation</i> , 2022, 145, 1398-1411.	5.0	24
59	Non-esterified fatty acids impair endothelium-dependent vasodilation in rat mesenteric resistance vessels. <i>Clinical Science</i> , 2004, 107, 625-629.	4.4	23
60	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. <i>Diabetologia</i> , 2021, 64, 1320-1331.	6.6	23
61	How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with Type 1 diabetes?. <i>Diabetic Medicine</i> , 2020, 37, 513-521.	2.5	20
62	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. <i>CJC Open</i> , 2021, 3, 1257-1272.	1.6	19
63	Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). <i>International Journal of Epidemiology</i> , 2016, 46, dyw152.	2.1	16
64	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiologyâ€œLed Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodiumâ€œGlucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq0 0 0 0 gBT /Overlock 10	9.3	15
65	New Pharmacological Approaches to Insulin and Lipid Metabolism. <i>Drugs</i> , 1994, 47, 701-710.	11.2	14
66	Dissecting Insulin Signaling Pathways: Individualised Therapeutic Targets for Diagnosis and Treatment of Insulin Resistant States. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2009, 9, 187-198.	1.3	14
67	Metformin and carotid intimaâ€œmedia thickness in neverâ€œsmokers with type <sc>1</sc> diabetes: The <sc>REMOVAL</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1371-1378.	4.6	14
68	Euglycemic Clamp Insulin Sensitivity and Longitudinal Systolic Blood Pressure. <i>Hypertension</i> , 2013, 62, 404-409.	5.0	13
69	LEADER-4. <i>Journal of Hypertension</i> , 2016, 34, 1140-1150.	0.5	13
70	What to add in with metformin in type 2 diabetes?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 185-192.	0.5	12
71	Longitudinal assessment of endothelial function in the microvasculature of mice in-vivo. <i>Microvascular Research</i> , 2013, 85, 86-92.	2.6	12
72	Diabetes is accompanied by changes in the levels of proteins involved in endosomal <sc>GLUT4</sc> trafficking in obese human skeletal muscle. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, .	2.4	12

#	ARTICLE	IF	CITATIONS
73	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. <i>Diabetes Care</i> , 2021, 44, 2010-2017.	9.3	11
74	Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. <i>Diabetes Care</i> , 2023, 46, 967-977.	9.3	11
75	One hour post-load plasma glucose and 3 year risk of worsening fasting and 2-hour glucose tolerance in the RISC cohort. <i>Diabetologia</i> , 2019, 62, 544-548.	6.6	10
76	Disruption of fasting and post-load glucose homeostasis are largely independent and sustained by distinct and early major beta-cell function defects: a cross-sectional and longitudinal analysis of the Relationship between Insulin Sensitivity and Cardiovascular risk (RISC) study cohort. <i>Metabolism: Clinical and Experimental</i> , 2020, 105, 154185.	3.7	10
77	Cohort profile: the Scottish Diabetes Research Network national diabetes cohort – a population-based cohort of people with diabetes in Scotland. <i>BMJ Open</i> , 2022, 12, e063046.	2.1	10
78	SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 841-843.	11.0	9
79	Knockout of syntaxin-4 in 3T3-L1 adipocytes reveals new insight into GLUT4 trafficking and adiponectin secretion. <i>Journal of Cell Science</i> , 2022, 135, .	2.1	9
80	Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2022, 146, 364-367.	5.0	9
81	Insulin-sensitising agents. <i>Expert Opinion on Emerging Drugs</i> , 1998, 3, 247-260.	1.1	8
82	Fludrocortisone therapy for persistent hyperkalaemia. <i>Diabetic Medicine</i> , 2017, 34, 1005-1008.	2.5	8
83	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2450-2458.	4.6	8
84	SGLT2 inhibitors and renal complications in type 1 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 803-805.	11.0	8
85	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017. <i>Diabetologia</i> , 2020, 63, 1626-1636.	6.6	8
86	Quantitative levels of serum N-glycans in type 1 diabetes and their association with kidney disease. <i>Glycobiology</i> , 2021, 31, 613-623.	2.9	8
87	A post COVID-19 “Marshall Plan” for type 2 diabetes. <i>Diabetic Medicine</i> , 2021, 38, e14439.	2.5	6
88	Specific insulin assays, insulin sensitivity and blood pressure. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1997, 90, 465-475.	0.5	5
89	Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control. Reply to Schatz H [letter]. <i>Diabetologia</i> , 2011, 54, 203-204.	6.6	5
90	Time in Range as a Research Outcome Measure. <i>Diabetes Spectrum</i> , 2021, 34, 133-138.	1.1	5

#	ARTICLE	IF	CITATIONS
91	Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure. <i>Hypertension</i> , 2022, 79, 36-46.	5.0	4
92	Prediabetes blunts DPP4 genetic control of postprandial glycaemia and insulin secretion. <i>Diabetologia</i> , 2022, 65, 861-871.	6.6	4
93	Recent developments in adjunct therapies for type 1 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1311-1320.	4.2	4
94	Evidence-based estimation of insulin resistance. <i>Diabetologia</i> , 2014, 57, 1743-1745.	6.6	3
95	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 139-140.	11.0	3
96	First among Equals: Macleod, Banting, and the Discovery of Insulin in Toronto. <i>Frontiers in Diabetes</i> , 2020, , 73-83.	0.0	3
97	Macrovascular disease: pathogenesis and risk assessment. <i>Medicine</i> , 2019, 47, 65-71.	0.5	2
98	<scp>LEADER</scp> and the new "cardiovascular"™ glucose-lowering agents. <i>Practical Diabetes</i> , 2016, 33, 187-189.	0.4	1
99	Renal function markers and insulin sensitivity after 3Âyears in a healthy cohort, the EGIR-RISC study. <i>BMC Nephrology</i> , 2018, 19, 124.	1.9	1
100	Cardiovascular disease in type 1 diabetes: the elephant in the clinic. <i>Cardiovascular Endocrinology and Metabolism</i> , 2019, 8, 1-2.	1.2	1
101	Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1929-1940.	4.6	1
102	Insulin-Stimulated Nitric Oxide Production in Human Aortic Endothelial Cells. <i>Biochemical Society Transactions</i> , 2001, 29, A70-A70.	3.5	0
103	Glucose in the coronary care unit. <i>Cardiovascular Endocrinology and Metabolism</i> , 2014, 3, 83-84.	1.2	0
104	Metformin in type 1 diabetes. <i>Practical Diabetes</i> , 2015, 32, 186.	0.4	0
105	Report of the European Group for the Study of Insulin Resistance annual meeting, Dublin, 4â€6th May 2017. <i>Cardiovascular Endocrinology</i> , 2017, Publish Ahead of Print, 113-116.	0.0	0
106	Expanding The Use Of Glucose Monitoring Technology To Enhance Diabetes Care. , 2018, , .		0
107	Quality of life in people with Type 2 diabetes; a study in a multi-ethnic clinical trial population. <i>British Journal of Diabetes</i> , 0, , .	0.2	0
108	Metformin beyond type 2 diabetes: Emerging and potential new indications. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 31-41.	4.6	0